FreeCME

Optimizing Treatment and Prevention of VTE in Patients with Hemotologic Malignancies

/ Print /
| ShareMore
/ Text Size +
12/10/21 7:00 pm EDT
Virtual Webinar



As incidence rates of cancer increase, so does the risk of disease or treatment-related complications. One of these complications, venous thromboembolism (VTE), is a well-established risk in patients with cancer, and can lead to morbidity or mortality. Thus, it is imperative for hematologists to have knowledge of VTE risk stratification, prophylaxis, management strategies, guideline-based recommendations for care, and the role of the multidisciplinary team. The goal of this virtual satellite symposium is to review the risks for VTE in patients with cancer, review prevention strategies, analyze recent clinical trials on treatments, and discuss the contributions of the multidisciplinary team across the continuum of care.

Learning Objectives

· Evaluate the risk of VTE in patients with cancer based on available risk-assessment tools

· Apply current evidence-based guidelines to make decisions regarding prophylaxis as well as treatment of VTE to mitigate risk for recurrence in patients with cancer

· Outline multidisciplinary care strategies for VTE prophylaxis and treatment in patients with cancer based on available clinical trial data

· Utilize risk-adapted strategies to mitigate the risk of developing recurrent VTE among patients with cancer based on evidence- and guideline-based approaches

Target Audience

This educational activity is directed toward medical oncologists, hematologist/oncologists, primary care providers, cardiologists, and other physicians who treat patients with cancer-related VTE. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with cancer-related VTE are also invited to attend.

Date

Friday, December 10, 2021

7:00 PM – 9:00 PM Eastern Time

Virtual Satellite Symposium!

 

Program Chair

Alok Khorana, MD
Professor of Medicine
Case Western Reserve University
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Cleveland, OH